HUE053310T2 - Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására - Google Patents

Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására

Info

Publication number
HUE053310T2
HUE053310T2 HUE18158960A HUE18158960A HUE053310T2 HU E053310 T2 HUE053310 T2 HU E053310T2 HU E18158960 A HUE18158960 A HU E18158960A HU E18158960 A HUE18158960 A HU E18158960A HU E053310 T2 HUE053310 T2 HU E053310T2
Authority
HU
Hungary
Prior art keywords
generating
light chain
same
genetically modified
chain antibodies
Prior art date
Application number
HUE18158960A
Other languages
English (en)
Inventor
John Mcwhirter
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE053310T2 publication Critical patent/HUE053310T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
HUE18158960A 2012-03-16 2013-03-15 Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására HUE053310T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611950P 2012-03-16 2012-03-16
US201261736930P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
HUE053310T2 true HUE053310T2 (hu) 2021-06-28

Family

ID=48045078

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE13713652A HUE039573T2 (hu) 2012-03-16 2013-03-15 Hisztidinnel módosított künnyûláncú antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
HUE18158960A HUE053310T2 (hu) 2012-03-16 2013-03-15 Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására
HUE15151655A HUE037659T2 (hu) 2012-03-16 2013-03-15 Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE13713652A HUE039573T2 (hu) 2012-03-16 2013-03-15 Hisztidinnel módosított künnyûláncú antitestek és genetikailag módosított rágcsálók ugyanennek az elõállítására

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15151655A HUE037659T2 (hu) 2012-03-16 2013-03-15 Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására

Country Status (26)

Country Link
US (3) US9334334B2 (hu)
EP (4) EP2825036B1 (hu)
JP (5) JP6185978B2 (hu)
KR (1) KR102228296B1 (hu)
CN (3) CN107827979A (hu)
AU (3) AU2013204579B2 (hu)
BR (1) BR112014022850A2 (hu)
CA (1) CA2865643A1 (hu)
CY (2) CY1120599T1 (hu)
DK (2) DK2883449T3 (hu)
ES (3) ES2665793T3 (hu)
HK (2) HK1200273A1 (hu)
HR (2) HRP20180682T1 (hu)
HU (3) HUE039573T2 (hu)
IL (5) IL234355B (hu)
LT (3) LT2883449T (hu)
MX (1) MX355732B (hu)
MY (1) MY172730A (hu)
NZ (1) NZ629639A (hu)
PL (2) PL2883449T3 (hu)
PT (3) PT2883449T (hu)
RS (2) RS57118B1 (hu)
RU (2) RU2644684C2 (hu)
SG (2) SG10201607689PA (hu)
SI (3) SI2883449T1 (hu)
WO (1) WO2013138680A1 (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102385507B1 (ko) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
US20140093496A1 (en) 2011-02-25 2014-04-03 Chugai Seiyaku Kabushiki Kaisha Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
KR20140100532A (ko) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
LT2825037T (lt) 2012-03-16 2019-08-12 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
CA2876172C (en) 2012-06-12 2021-01-19 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2729831C2 (ru) 2012-08-24 2020-08-12 Чугаи Сейяку Кабусики Кайся ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP5993102B2 (ja) 2013-02-20 2016-09-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾された免疫グロブリン重鎖配列を有する非ヒト動物
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN106459192B (zh) * 2014-06-30 2021-08-03 默克专利股份公司 具有pH依赖性抗原结合的抗TNFa抗体
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
JP2018511557A (ja) * 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
CN114773469A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016191659A1 (en) 2015-05-28 2016-12-01 Bio-Rad Laboratories, Inc. Affinity ligands and methods relating thereto
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102467124B1 (ko) * 2015-12-18 2022-11-15 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 사용 방법
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3457840B1 (en) 2016-05-20 2024-04-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
DK3462853T3 (da) 2016-06-03 2023-04-03 Regeneron Pharma Gnavere, der udtrykker exogen, terminal deoxynukleotidyltransferase
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
GB201707484D0 (en) * 2017-05-10 2017-06-21 Argenx Bvba Method of preparing ph-dependent antibodies
EP3765498A1 (en) * 2018-03-14 2021-01-20 F. Hoffmann-La Roche AG Method for affinity maturation of antibodies
AU2019242551A1 (en) 2018-03-24 2020-10-22 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-MHC complexes, methods of making and uses thereof
EP3772926A1 (en) 2018-03-26 2021-02-17 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
HRP20220509T8 (hr) 2018-06-14 2022-07-22 Regeneron Pharmaceuticals, Inc. Ne-humane životinje sposobne za dh-dh preraspodjelu kodirajućim sekvencama teškog lanca imunoglobulina
JP6935383B2 (ja) * 2018-09-27 2021-09-15 公益財団法人実験動物中央研究所 免疫不全マウス
WO2020204040A1 (ja) 2019-04-04 2020-10-08 日精エー・エス・ビー機械株式会社 樹脂製容器の製造方法、射出コア型、射出成形用金型および樹脂製容器の製造装置
JP2022535418A (ja) 2019-06-05 2022-08-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
US11773156B2 (en) * 2019-10-28 2023-10-03 Regeneron Pharmaceuticals, Inc. Anti-hemagglutinin antibodies and methods of use thereof
AU2021320739A1 (en) * 2020-08-04 2023-02-23 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
EP4208258A1 (en) 2020-09-03 2023-07-12 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a pd-1 inhibitor
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CA2075927A1 (en) 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7067284B1 (en) 1992-01-27 2006-06-27 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5999908A (en) 1992-08-06 1999-12-07 Abelow; Daniel H. Customer-based product design module
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0843961B1 (en) 1995-08-29 2007-01-24 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
DK1317537T3 (da) 2000-09-08 2007-04-30 Massachusetts Inst Technology Sammensætninger og fremgangsmåder med G-CSF analoger
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
EP2107116A3 (en) 2002-06-12 2009-12-09 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
EP1439234A1 (en) 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
WO2004065611A1 (ja) 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
ES2473596T3 (es) 2003-07-15 2014-07-07 Therapeutic Human Polyclonals, Inc. Loci de inmunoglobulina humanizada
CN1560081A (zh) 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
JP2008520552A (ja) 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
US20080196112A1 (en) 2005-04-29 2008-08-14 Innate Pharma, S.A. Transgenic Animals and Methods of Making Recombinant Antibodies
EP1966241A2 (en) 2005-12-05 2008-09-10 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
EP2003960B1 (en) 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2445318C2 (ru) 2006-10-02 2012-03-20 Ридженерон Фармасьютикалз, Инк. Высокоаффинные антитела человека к рецептору il-4 человека
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2583551A1 (en) 2007-03-13 2013-04-24 National Jewish Health Methods for generation of antibodies
ITMI20071522A1 (it) 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CN110698561A (zh) 2007-12-14 2020-01-17 诺沃—诺迪斯克有限公司 抗人nkg2d抗体及其用途
NZ602884A (en) * 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9315577B2 (en) * 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
MX2010014542A (es) 2008-06-27 2011-04-05 Merus B V Mamiferos no humanos los cuales producen anticuerpos.
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR101826224B1 (ko) * 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2747534C (en) 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
RU2011149353A (ru) 2009-05-07 2013-06-20 Вольво Констракшн Эквипмент Аб Рабочая машина и способ управления ее работой
MX2011012696A (es) 2009-05-29 2012-03-29 Morphosys Ag Una coleccion y metodos para su uso.
CN102471378B (zh) 2009-06-26 2014-04-02 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
CA2767957C (en) 2009-07-16 2020-08-25 Wageningen Universiteit Regulation of zinc deficiency and tolerance in plants
GB2472108B (en) * 2009-08-27 2011-07-13 Budha Singh Dhinjan Wall bead
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JP5932670B2 (ja) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
CN104404050B (zh) 2010-06-22 2018-06-08 瑞泽恩制药公司 杂交轻链小鼠
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
CA3186007A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Ion concentration-dependent binding molecule library
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
RU2683514C2 (ru) 2012-03-06 2019-03-28 Регенерон Фармасьютикалз, Инк. Мышь с общей легкой цепью
LT2825037T (lt) 2012-03-16 2019-08-12 Regeneron Pharmaceuticals, Inc. Graužikai, ekspresuojantys ph jautrias imunoglobulino sekas
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014153674A (ru) 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JP5993102B2 (ja) 2013-02-20 2016-09-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾された免疫グロブリン重鎖配列を有する非ヒト動物

Also Published As

Publication number Publication date
US20130247234A1 (en) 2013-09-19
US9334334B2 (en) 2016-05-10
CN104302169A (zh) 2015-01-21
JP7304169B2 (ja) 2023-07-06
HK1200273A1 (en) 2015-08-07
SI2825036T1 (en) 2018-08-31
RS57118B1 (sr) 2018-06-29
US11192947B2 (en) 2021-12-07
EP3348140B1 (en) 2020-12-30
PL2883449T3 (pl) 2018-07-31
CY1120491T1 (el) 2019-07-10
ES2665793T3 (es) 2018-04-27
DK2883449T3 (en) 2018-04-23
ES2679369T3 (es) 2018-08-24
JP2017104139A (ja) 2017-06-15
SG11201405165UA (en) 2014-10-30
SI3348140T1 (sl) 2021-03-31
AU2018203713B2 (en) 2020-12-24
MX2014011051A (es) 2015-04-08
KR20140135193A (ko) 2014-11-25
HUE037659T2 (hu) 2018-09-28
IL282452B (en) 2022-03-01
IL244097A (en) 2017-06-29
EP3808175A1 (en) 2021-04-21
EP3348140A2 (en) 2018-07-18
US20140329711A1 (en) 2014-11-06
RS57414B1 (sr) 2018-09-28
CY1120599T1 (el) 2019-12-11
IL244097A0 (en) 2016-04-21
SG10201607689PA (en) 2016-10-28
US9422370B2 (en) 2016-08-23
LT2825036T (lt) 2018-07-10
EP2825036B1 (en) 2018-05-02
EP2883449B1 (en) 2018-02-07
HUE039573T2 (hu) 2019-01-28
RU2644684C2 (ru) 2018-02-13
RU2014141537A (ru) 2016-05-20
RU2017135754A (ru) 2019-02-08
PT2825036T (pt) 2018-07-26
AU2013204579B2 (en) 2016-01-14
CN104302169B (zh) 2017-11-17
JP6574802B2 (ja) 2019-09-11
CN107840890A (zh) 2018-03-27
IL234355B (en) 2018-07-31
IL282452A (en) 2021-06-30
KR102228296B1 (ko) 2021-03-17
BR112014022850A2 (pt) 2017-07-18
WO2013138680A1 (en) 2013-09-19
AU2016202323A1 (en) 2016-05-05
MX355732B (es) 2018-04-27
JP2022017547A (ja) 2022-01-25
IL272357B (en) 2021-05-31
JP2020108404A (ja) 2020-07-16
AU2013204579A1 (en) 2013-10-03
JP7199398B2 (ja) 2023-01-05
PL2825036T3 (pl) 2018-10-31
AU2018203713A1 (en) 2018-06-21
JP2015510767A (ja) 2015-04-13
LT2883449T (lt) 2018-05-10
NZ629639A (en) 2017-03-31
MY172730A (en) 2019-12-11
DK2825036T3 (en) 2018-07-16
HK1205642A1 (en) 2015-12-24
IL253775B (en) 2020-02-27
IL272357A (en) 2020-03-31
JP2019071910A (ja) 2019-05-16
JP6185978B2 (ja) 2017-08-23
HRP20180682T1 (hr) 2018-06-01
CA2865643A1 (en) 2013-09-19
US20160311899A1 (en) 2016-10-27
CN107827979A (zh) 2018-03-23
IL253775A0 (en) 2017-09-28
HRP20181228T1 (hr) 2018-10-05
EP2883449A1 (en) 2015-06-17
LT3348140T (lt) 2021-01-25
PT3348140T (pt) 2021-01-07
RU2017135754A3 (hu) 2021-01-27
EP2825036A1 (en) 2015-01-21
AU2016202323B2 (en) 2018-03-01
ES2849349T3 (es) 2021-08-17
SI2883449T1 (en) 2018-05-31
WO2013138680A4 (en) 2013-11-07
EP3348140A3 (en) 2018-10-03
PT2883449T (pt) 2018-05-07

Similar Documents

Publication Publication Date Title
HRP20181228T1 (hr) Antitijela lakog lanca proizvedena histidinom i genetski modificirani glodavci za njihovu proizvodnju
IL264358A (en) Histidine engineered light chain antibodies and non-human animals genetically engineered to produce them
HK1216899A1 (zh) 工程化免疫球蛋白重鏈-輕鏈對及其用途
EP2863736A4 (en) GENETICALLY MODIFIED ANIMALS AND METHODS OF PRODUCTION THEREFOR
EP2678434A4 (en) GENETICALLY MODIFIED ANIMALS AND METHODS FOR PRODUCING THE SAME
GB201305732D0 (en) Photonic and/or optoelectronic packaging assembly
EP3001185A4 (en) OPTICAL GRANULATOR
TWI560906B (en) Semiconductor light emitting device and method for manufacturing the same
HUE037613T2 (hu) Anti-TLR4 antitestek és azok felhasználása
HK1205145A1 (en) Improved antibody light chains
TWI563066B (en) Compound and organic light emitting device including the same
TWI562428B (en) Organic light emitting device and method for preparing the same